safinamide has been researched along with Disease Exacerbation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Larson, D; Simuni, T | 1 |
| Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA | 1 |
| Abreu, D; Fabbri, M; Ferreira, JJ; Rosa, MM | 1 |
| Schapira, AH | 1 |
4 review(s) available for safinamide and Disease Exacerbation
| Article | Year |
|---|---|
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2014 |
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; Humans; Molecular Structure; Parkinson Disease | 2015 |
Safinamide in the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; Humans; Parkinson Disease; Treatment Outcome | 2010 |